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j ourna l homepage: www.e lsev ie r .com/ locate /bbad isPrefaceEmerging potential of therapeutic targeting of autophagy and protein
quality control in the management of cardiometabolic diseases☆We are delighted and thrilled to serve as editors for this special issue
of “BBAMol Basis Disease” on “Autophagy and protein quality control in
cardiometabolic disease”. Our enthusiasm for this special topic rooted
from the profound protein damage in individuals with cardiovascular
diseases in particular ischemic/reperfusion injury, diabetes mellitus,
insulin resistance, obesity and hypertension [1–4]. Although recent
advances in medical technology and health care have drastically
improved the success of early diagnosis andmanagement for cardiovas-
cular diseases, the ever-rising prevalence for metabolic issues including
obesity, diabetesmellitus, insulin resistance, hypertension and dyslipid-
emia, collectively known as cardiometabolic diseases, continues to
serve as main contributing risk factors for cardiovascular morbidity
and mortality in our modern society [1,5]. Despite numerous available
studies and clinical trials in the ﬁeld of cardiometabolic diseases, the
underlying pathological mechanisms remain essentially elusive for
these comorbidities, which hinder the appropriate management of car-
diovascular events [6–8]. Up-to-date, a number of theories have been
put forward for the pathogenesis of cardiometabolic disease including
insulin resistance, abnormal glucose and lipid metabolism, oxidative
and nitrosative/nitrative stress, endoplasmic reticulum (ER) stress, apo-
ptosis, mitochondrial damage, low-grade inﬂammation, and the satiety
lifestyle [1,5,9,10]. More recent evidence suggests an essential role for
proteotoxicity, which refers to the detrimental effects of damaged pro-
teins for cells and organisms, in cardiovascular in particular cardiomet-
abolic diseases [11]. Protein quality control is governed mainly by the
ubiquitin–proteasome system (UPS) and autophagy-lysosomal path-
ways, representing two major although distinct cellular machineries
for the degradation and removal of most proteins [3,11]. UPS degrades
the majority of proteins, whereas autophagy is a highly conserved pro-
cess by which intracellular components, including soluble macromole-
cules (e.g. nucleic acids, proteins, carbohydrates, lipids) and defective
organelles (e.g. mitochondria, ribosomes, peroxisomes, and ER) are de-
graded by the lysosome. Disruption of these processes triggers patho-
logical sequelae, leading to proteotoxic alterations in cardiovascular
diseases such as idiopathic, hypertrophic, ischemic, and pressure-
overloaded cardiomyopathies [2,11]. To optimize effective therapeutic
regimes, it is imperative to better our understanding for the precise
role for protein quality control in the onset and pathogenesis of cardio-
metabolic syndrome. This special issue of “BBA Molecular Basis Disease”
tackles some of the burning issues on protein quality control through☆ Preface for the BBA Mol Basis Disease Special Issue— “Autophagy and protein quality
control in cardiometabolic diseases”.
http://dx.doi.org/10.1016/j.bbadis.2014.11.002
0925-4439/© 2014 Elsevier B.V. All rights reserved.machineries of autophagy andUPS in the pathogenesis and therapeutics
of cardiometabolic disease.
In the ﬁrst article of this series, Wang and Wang reviewed the
current understanding for the role of UPS and autophagy in the regula-
tion of cardiac proteotoxicity, and then addressed crosstalk mechanism
between these two pathways. Although UPS and autophagy are distinct
protein degradation pathways (e.g., small versus large molecules),
crosstalk exists between these two degradation machineries.
Proteasomal inhibition activates autophagy. However, autophagy
inhibition elicits somewhat complex effect on proteasome peptidase
activities depending on the duration of suppressed autophagy [2]. In
the second article, Hua and Nair discussed the promises of targeting
major proteases including matrix metalloproteinase (MMP), cathep-
sins, calpains and caspases in the therapeutics of cardiometabolic
diseases. Elevated levels and/or activities of proteases have been docu-
mented in atherosclerosis, coronary heart disease, obesity and insulin
resistance, concurrent with the application of proteases as key bio-
markers for cardiometabolic diseases. Hua and Nair further discussed
the salutary effects and potential mechanisms behind protease inhibi-
tors in cardiometabolic diseases [12]. In the third article, Yang and her
colleagues tackled the interplay between ER stress and protein quality
control in diabetic cardiomyopathy. ER stress, an early event found in
diabetic cardiomyopathy, may be triggered by hyperglycemia, free
fatty acids (FFAs) and inﬂammation. These authors discussed how ER
stress in response to these triggers may interfere with ER integrity,
autophagy, and ultimately development of diabetic cardiomyopathy
[13]. The fourth article by Sowers and coworkers thoroughly discussed
potential contribution of dysregulated autophagy in the development
of cardiorenalmetabolic syndrome, including insulin resistance, obesity,
hypertension, maladaptive immunity. The authors dissected how
cellular protein quality control by way of the disposal and recycling
of cellular components might participate in the pathogenesis of
cardiorenal metabolic syndrome [14]. The ﬁfth article by Xu and
colleagues discussed how autophagy is involved in the regulation of
cardiac function in cardiometabolic syndrome. They discussed the ther-
apeutic potential of targeting autophagy in the management of cardiac
complications under metabolic anomalies such as diet-induced obesity
[15]. In the next article, Varga and colleagues provided insights into
the complex interplay of oxidative/nitrosative stress en route to
pro-inﬂammatory and pro-apoptotic outcomes in the pathogenesis of
diabetic cardiomyopathy. They went on to discuss how superoxide
produced by mitochondria, NADPH oxidases and xanthine oxidoreduc-
tase may interact with nitric oxide (NO) to form the potent toxin
peroxynitrite, to turn on stress kinases, ER stress, mitochondrial and
186 Prefacepoly(ADP-ribose) polymerase 1-dependent cell death. As a result, the
autophagy/mitophagy homeostasis is interrupted, leading to impaired
protein control for myocardial Ca2+ handling, contractility, antioxidant
defense, MMP and pro-inﬂammatory transcription factors, which all
contribute to the development of diabetic cardiomyopathy [16]. In the
seventh article, Mei and colleagues further elucidated the delicate inter-
play between oxidative stress and autophagy. They emphasized the
dual regulatory (double-edged sword) role for autophagy in the cardio-
vascular homeostasis. Full appreciation of autophagy as either adaptive
or maladaptive response provides potential new strategies for the pre-
vention and management of cardiovascular diseases [17]. In the eighth
article, Kobayashi and Liang discussed the unique role of mitophagy, or
elimination of damagedmitochondria through autophagy, in myocardial
mitochondrial injury in diabetes. They dissected the disparate roles for
autophagy in particularmitophagy in type 1 and type 2 diabetes, suggest-
ing an adaptive role for the diminished autophagy in cardiac injury asso-
ciated with type 1 diabetes [18]. In the ninth article, Xu and colleagues
examined the role of mitochondrial c-Jun N-terminal kinase (JNK) in
ischemic heart injury. These investigators reported that activation of mi-
tochondrial JNK, rather than localization of JNK on mitochondria, may
induce autophagy and apoptosis to aggravate ischemia/reperfusion inju-
ry [19]. In the next article of this series, Ma and colleagues succinctly dis-
sected the compelling dual roles for autophagy in ischemia–reperfusion
injury. These authors elaborated the cellular mechanisms underneath
beneﬁcial and detrimental effects of autophagy in the pathology of
cardiac ischemia reperfusion injury [20].
In the second half of this special series, the impact of a number of
enzymes or proteins on homeostasis of autophagy, protein quality con-
trol, structure and function was addressed. In the ﬁrst article, Bouhidel
and colleagues reported cardioprotection offered by a novel protein
netrin-1 in ischemia–reperfusion injury. Their ﬁnding revealed that
the netrin-1-offered beneﬁcial effect is mediated through the receptor
from the deleted in colorectal cancer (DCC) and NO-dependent preser-
vation of mitochondria while attenuating autophagy, suggesting the
therapeutic potential of netrin-1 for myocardial infarction (MI) and
post-MI remodeling [21]. In the second article, Roe and colleagues
generated a cardiomyocyte-speciﬁc knockout of phosphatase and
tensin homologue deleted from chromosome 10 (PTEN). Their work
suggested a role for the loss of Pink1–AMPK signaling, interrupted
autophagy and autophagic ﬂux in the development of cardiac hypertro-
phy and contractile defect [22]. In the third article, Kandadi and
coworkers examined another protein phosphatase namely protein tyro-
sine phosphatase-1B (PTP1B), a negative regulator of insulin signaling,
in high fat diet-induced obesity. These authors reported that high fat
diet compromised cardiac function, promoted cardiac remodeling and
lipid accumulation, which were attenuated by PTP1B knockout. PTP1B
knockout reversed high fat diet-induced loss of autophagy likely via
an AMPK-dependent mechanism [23]. In the fourth article, Shen and
colleagues reported that deﬁciency inmitochondrial aldehyde dehydro-
genase (ALDH2), which is common in subsets of human population,
exacerbated aortic constriction-induced cardiac defect and loss of
autophagy. These data indicate that ALDH2 enzymatic deﬁciency may
worsen pressure overload-induced cardiac dysfunction partly by inhibi-
tion of Beclin-1-dependent autophagy [24], which presents unique
clinical relevance. The ﬁfth article of this series also addressed the
autophagy regulatory role of ALDH2 in diabetes where ALDH2 trans-
gene rescued the heart against diabetic cardiomyopathy (compromised
function and cardiac hypertrophy) along with facilitated autophagy.
Inhibition of autophagy and AMPK mitigated ALDH2-offered beneﬁcial
effect, suggesting a possible role of autophagy in ALDH2-offered protec-
tion against diabetes [25]. Thesework using experimental pressure over-
load and diabetic models favor a unique cardioprotective role for the
mitochondrial chaperon ALDH2 through facilitated cardiac autophagy.
In the sixth article of this series, Zheng and colleagues examined the
role of the essential energy fuel signal AMPK in prolonged caloric
restriction-induced change in the maintenance of cardiac homeostasis.Caloric restriction may compromise echocardiographic function, cardio-
myocyte contractile and intracellular Ca2+ properties in associationwith
upregulated autophagy. Interestingly, AMPK inhibition reversed caloric
restriction-induced changes in autophagy and autophagy signaling.
AMPK inhibition led to dampened autophagy, suggesting an indispens-
able role for AMPK in the maintenance of cardiac homeostasis under ca-
loric restriction [26]. Given that the master energy fuel regulator AMPK
helps to promote energy supply and cut downanabolism, it is reasonable
to speculate the indispensable role for AMPK in the maintenance of
cardiac homeostasis under starvation. In the seventh article of this series,
Liang and colleagues examined the role of the antioxidant catalase in fat
diet-induced changes in cardiac autophagy, geometry and function.
Myocardial geometry and function were compromised with fat diet
intake, the effects of which were ameliorated by catalase. High fat diet
intake promoted reactive oxygen species (ROS) generation and sup-
pressed autophagy in the heart, the effects of which were attenuated
by catalase, possibly via an IKKβ-AMPK-dependent restoration of
myocardial autophagy [27]. In the eighth article of this section, Yan and
colleagues examined the role of a novel cellular repressor of E1A gene
(Creg1), an evolutionarily conserved lysosomal protein, in myocardial
ﬁbrosis in the face of aging or angiotensin II (Ang II) exposure. These
authors observed accumulation of autophagesomes and interruption of
autophagic ﬂux under Creg1 deﬁciency, depicting a unique role for
Creg1 as a viable therapeutic target for pathological cardiac condi-
tions [28]. In the last article of this series, Zhao and Li reviewed the role
of the interferon-regulatory factor (IRF) transcriptional factor family in
the regulation of cell survival processes such as metabolism. These au-
thors discussed the novel stress-responsive regulatory role for IRFs [29].
Although the collections in this special issue have shed some insights
toward the better understanding of autophagy and protein quality
control in the regulation of cardiac homeostasis in cardiometabolic
diseases, it is noteworthy that the topics described here probably raise
more questions than answers. First, given the availability of genetically
engineered murine models of autophagy, it is desirable to conduct a
“proof of concept” type of research in cardiometabolic diseases. Second,
like all animal models, animal or cell models for human cardiometabolic
disease suffer from limitation tomimic the scope of pathological changes
under the clinical cardiometabolic syndrome setting. Special caution
needs to be taken to employ the bench-side concept to the bed-side
practice. Third, given the complexity in the etiology of cardiometabolic
diseases, it remains challenging to pinpointwhich intervention targeting
autophagy may be more superior. We hope that this special series will
help identify novel therapeutic targets to launch better intervention
regimens for the management of cardiometabolic diseases.
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